How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
A full-length ORF (Open Reading Frame) Clone Market
- By Clone Type: Gateway Clones, TOPO Clones, Entry Clones, Expression Clones, Custom Clones
- By Vector Type: Mammalian Expression Vectors, Bacterial Expression Vectors, Yeast Expression Vectors, Insect Expression Vectors, Cell-Free Expression Vectors
- By Application: Protein Expression, Functional Genomics, Gene Function Studies, Drug Discovery, Antibody Production
- By Gene Source: Human ORF Clones, Mouse ORF Clones, Rat ORF Clones, Plant ORF Clones, Microbial ORF Clones
- By Product Format: Plasmid DNA, Lentiviral Particles, Bacterial Glycerol Stocks, Ready-to-Transfect DNA, Custom Synthesized ORFs
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gateway Clones leads By Clone Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the A full-length ORF (Open Reading Frame) Clone Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Clone Type 5
Vector Type 5
Application 5
Gene Source 5
Product Format 5
Companies profiled
GenScript Biotech Corporation
OriGene Technologies Inc.
Addgene Inc.
Twist Bioscience Corporation
Thermo Fisher Scientific Inc.
Integrated DNA Technologies
Inc. (IDT)
GeneCopoeia Inc.
VectorBuilder Inc.
BioBasic Inc.
GenScript USA Inc.
GenScript ProBio
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GenScript Biotech Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →OriGene Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Addgene Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Twist Bioscience Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Integrated DNA Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (IDT)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →GeneCopoeia Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →VectorBuilder Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BioBasic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GenScript USA Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GenScript ProBio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Creative Biogene
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GeneArt (Thermo Fisher Scientific)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sino Biological Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Abcam plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,084M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gateway Clones50.3
- TOPO Clones21.0
- Entry Clones7.5
- Expression Clones10.2
- Custom Clones10.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,503M → $3,253M · 10.1%
Europe$1,048M → $2,288M · 10.3%
Asia Pacific$956.6M → $2,188M · 10.9%
Latin America$592.2M → $1,449M · 11.8%
Middle East and Africa$455.5M → $961.8M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.402026
10.412027
10.412028
10.432029
10.442030
10.452031
10.472032
10.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GenScript Biotech Corporation20.9
- OriGene Technologies Inc.19.2
- Addgene Inc.3.6
- Twist Bioscience Corporation10.1
- Thermo Fisher Scientific Inc.8.9
- Integrated DNA Technologies9.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Clone Type32.1%
Vector Type10.9%
Application12.2%
Gene Source14.6%
Product Format30.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe22.6
- Asia Pacific21.6
- Latin America14.3
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GenScript Biotech Corporation | 80 | 78 | 75 | 74 | 79 | 75 | 77 |
| OriGene Technologies Inc. | 78 | 74 | 88 | 86 | 89 | 75 | 82 |
| Addgene Inc. | 79 | 88 | 87 | 86 | 74 | 84 | 83 |
| Twist Bioscience Corporation | 61 | 62 | 75 | 75 | 75 | 60 | 68 |
| Thermo Fisher Scientific Inc. | 68 | 64 | 62 | 71 | 71 | 66 | 67 |
| Integrated DNA Technologies | 57 | 57 | 70 | 65 | 47 | 47 | 57 |
| Inc. (IDT) | 60 | 58 | 48 | 62 | 54 | 61 | 57 |
| GeneCopoeia Inc. | 59 | 44 | 46 | 36 | 56 | 41 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GenScript Biotech Corporation
- OriGene Technologies Inc.
- Addgene Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GenScript Biotech Corporation | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| OriGene Technologies Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Addgene Inc. | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Twist Bioscience Corporation | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Thermo Fisher Scientific Inc. | ✓ | ◐ | − | − | − | ✓ |
| Integrated DNA Technologies | ◐ | − | − | ◐ | − | − |
| Inc. (IDT) | − | − | ◐ | ◐ | ◐ | ◐ |
| GeneCopoeia Inc. | ◐ | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Addgene Inc.83
2OriGene Technologies Inc.82
3GenScript Biotech Corporation77
4Twist Bioscience Corporation68
5Thermo Fisher Scientific Inc.67
6Integrated DNA Technologies57
7Inc. (IDT)57
8GeneCopoeia Inc.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
OriGene Technologies Inc.Addgene Inc.
Challenger3
Strong scale, closing on the leaders.
GenScript Biotech CorporationTwist Bioscience CorporationThermo Fisher Scientific Inc.
Contender2
Focused players with pockets of strength.
Integrated DNA TechnologiesInc. (IDT)
Niche1
Specialists in a single segment or region.
GeneCopoeia Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Clone Type in North America, then scale across A full-length ORF (Open Reading Frame) Clone Market — a $202M beachhead inside a $2.72B market.
Beachhead (SOM)$202Mobtainable near-term
Serviceable (SAM)$1.12Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Gateway Clones
Best fit — highest urgency & budget in Clone Type.
Economic buyer80 fit
TOPO Clones
Strong fit — clear ROI and a fast path to value.
End user67 fit
Entry Clones
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Clone Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vector Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Clone Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win A full-length ORF (Open Reading Frame) Clone Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified22%
Evaluation13%
Closed-won7%
$8.5KCAC
$37KLTV
4.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
A full-length ORF (Open Reading Frame) Clone Market is a durable-growth opportunity — $5.15B by 2033, compounding at 6.1%.
TAM · 2025$3.20Btoday
TAM · 2033$5.15Bforecast
CAGR6.1%2027–2033
Cumulative$37.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.15BTotal addressable market
SAM$1.87BServiceable available market
SOM$311MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.1% CAGR
Demand compounds through 2033, outpacing GDP across Clone Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Clone Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.15BLarge & growingTAM by 2033 at 6.1% CAGR
$1.87BServiceable nowreachable with today’s model
$311MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.02BBear4.0% CAGR
$5.15BBase6.1% CAGR
$6.60BBull8.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vector Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
A full-length ORF (Open Reading Frame) Clone Market — a $11.0B market by 2033. Plan: grow share from 8.1% to 14.5%.
Market size · 2033$11.0Btotal addressable
Market CAGR11.2%2027–2033
Target share14.5%from 8.1% today
Revenue ambition$1.60Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 14.5% | Behind |
| Revenue | $958M | $1.60B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 37.9% | 40.0% | On track |
| Customer retention | 84.6% | 95.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Clone Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vector Type capability
A defensible second engine — invest in Vector Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Clone Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vector Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $227M capacity & capability investment
- Greenlight bolt-on M&A in Vector Type
- Authorise North America expansion plan
- Fund R&D program for Clone Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the A full-length ORF (Open Reading Frame) Clone Market conversation — a $8.15B market you can size, segment and defend in minutes.
Market size · 2033$8.15Btotal opportunity
Growth5.4%CAGR to 2033
Addressable buyers1,141+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Clone Type
Goal Grow share in Clone Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 4 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
GenScript Biotech CorporationOriGene Technologies Inc.Addgene Inc.Twist Bioscience CorporationThermo Fisher Scientific Inc.Integrated DNA TechnologiesInc. (IDT)GeneCopoeia Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your A full-length ORF (Open Reading Frame) Clone Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
A full-length ORF (Open Reading Frame) Clone Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →mHealth Applications Market
Market size, share, segmentation and regional forecast.
$720M market · 2025 base year
View reportKnowledge Management in Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportAfter Hours Medical Service Market
Market size, share, segmentation and regional forecast.
$385M market · 2025 base year
View reportDrug Discovery Software Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAfter Acute Ischemic Stroke Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportAfrican Swine Fever Virus Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAfrican Swine Fever Antigen Rapid Detection Kit Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportElectronic Lab Notebook (ELN) Software Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportVendor-Neutral Archives (VNA) Software Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAfoxolaner Market
Market size, share, segmentation and regional forecast.
$585M market · 2025 base year
View reportPrivate Duty Home Care Software Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportAfoxolaner Chewable Tablets Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.